Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].

Core Viewpoint - The approval of Yipeisheng (益佩生), a long-acting growth hormone injection by Tebao Biopharma, marks a significant shift in the long-acting growth hormone market, breaking the decade-long monopoly held by Jinsai Pharmaceutical [2][4]. Company Summary - Tebao Biopharma's Yipeisheng is designed for weekly administration, targeting growth hormone deficiency in children aged three and above, enhancing patient compliance and reducing treatment burden [2][3]. - The company reported a revenue of 2.817 billion yuan in 2024, a year-on-year increase of 34.13%, and a net profit of 828 million yuan, up 49% year-on-year [6]. - The company has five existing products, with Paigebin being the main revenue driver, generating 2.447 billion yuan, accounting for over 80% of total revenue [6]. Industry Summary - The long-acting growth hormone market has been dominated by Jinsai Pharmaceutical for over ten years, with its product "Jinsai Zeng" being the first globally approved long-acting growth hormone [3][4]. - The market for growth hormone treatment in China is significant, with approximately 6.4 million children affected by growth hormone deficiency, indicating a substantial unmet medical need [3]. - The entry of Yipeisheng is expected to intensify competition in the long-acting growth hormone sector, potentially leading to expanded indications and increased market share for long-acting products [4].

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688278 证券简称：特宝生物 公告编号：2025-020 厦门特宝生物工程股份有限公司 关于怡培生长激素注射液获批上市的公告 2025年5月29日，国家药品监督管理局官方网站公示，厦门特宝生物工程股份 有限公司（以下简称"公司"）申报的怡培生长激素注射液（商品名：益佩生）获 批上市。现将有关情况公告如下： 一、药品基本情况 药品名称：怡培生长激素注射液 商品名称：益佩生® 剂 型：注射剂 申请事项：境内生产药品注册上市许可 上市许可持有人：厦门特宝生物工程股份有限公司 生产企业：厦门特宝生物工程股份有限公司 适应症：适用于治疗3岁及以上儿童的生长激素缺乏症所致的生长缓慢。 二、药品相关情况 人生长激素是在垂体前叶生成的单链非糖基化多肽，具有调节代谢、刺激蛋白 质合成和加速脂肪代谢等生理功能，能促进骨骼和肌肉组织的生长发育。怡培生长 激素具有与人体内源生长激素同等的作用。 三、对公司的影响及风险提示 益佩生的获批上市，进一步完善了公司的产品矩阵，增强公司满足不同患者 ...

Group 1 - The core point of the news is that Tonghua Dongbao plans to transfer 23.1876 million shares of Tebao Bio, reducing its stake from 16.03% to 10.33% after the transfer, which amounts to a total transaction value of 1.301 billion yuan at a price of 56.12 yuan per share [1] - Tonghua Dongbao has been a long-term partner of Tebao Bio since its establishment in 2000 and has gradually reduced its stake since the lifting of share restrictions, realizing investment returns [1][2] - The share transfer is part of Tonghua Dongbao's strategy to enhance its innovation-driven transformation and improve asset utilization, which is expected to significantly boost its net profit and earnings per share in the second quarter [2] Group 2 - Tebao Bio's stock price increased by 6.31% in the first quarter, with a current market value of 30.3 billion yuan, and it has entered the top ten heavy stocks of 32 funds [2] - Tebao Bio's revenue has grown from 794 million yuan in 2020 to 2.817 billion yuan in 2024, while net profit increased from 117 million yuan to 828 million yuan during the same period [2] - Tonghua Dongbao's recent financial struggles are attributed to a new round of insulin procurement that began last year, leading to a decline in sales and profits, with a projected revenue of 2.009 billion yuan for 2024, a decrease of 34.66% year-on-year [3]

Group 1 - The China Securities 500 Quality Growth Index (930939) increased by 0.59% as of May 23, 2025, with notable gains from Huahai Pharmaceutical (600521) at 8.66%, Betta Pharmaceuticals (300558) at 6.12%, and Xinlitai (002294) at 5.79% [1] - The 500 Quality Growth ETF (560500) rose by 0.75%, with the latest price at 0.95 yuan [1] - The Chief Risk Officer announced a more flexible and precise issuance counter-cyclical adjustment mechanism to better align investment and financing in the capital market [1] Group 2 - Bohai Securities indicated that future market opportunities will depend on incremental changes, suggesting that in case of unexpected downturns due to external risks or investor sentiment, investors should consider counter-cyclical strategies [2] - The report emphasized a "barbell" allocation strategy, focusing on high-dividend and relatively underweighted banking sectors, while also looking for thematic investment opportunities in mergers and acquisitions and new consumption sectors [2] - The 500 Quality Growth Index selects 100 companies with high profitability, sustainable earnings, and strong cash flow from the China Securities 500 Index, providing diverse investment options [2] Group 3 - As of April 30, 2025, the top ten weighted stocks in the China Securities 500 Quality Growth Index accounted for 24.07% of the index, with Chifeng Jilong Gold Mining (600988) being the highest at 3.13% [3] - The top ten stocks include companies like Ninebot (689009), Kaiying Network (002517), and Shenghong Technology (300476), with varying weightings and performance [5]

Core Viewpoint - The announcement details the agreement for a share transfer involving Xiamen Te Bao Biological Engineering Co., Ltd., where a major shareholder, Tonghua Dongbao Pharmaceutical Co., Ltd., plans to transfer 23,187,600 shares to Tibet Trust Co., Ltd. at a price of 56.12 yuan per share, representing 5.70% of the company's total share capital [1][2]. Summary by Sections 1. Basic Situation of the Equity Change - Tonghua Dongbao intends to transfer 23,187,600 shares at a price of 56.12 yuan per share, totaling approximately 1.301 billion yuan [1][4]. - Post-transfer, Tonghua Dongbao will hold 42,012,514 shares, accounting for 10.33% of the total share capital, while Tibet Trust will hold 23,187,600 shares, representing 5.70% [1][2]. 2. Commitment from Tibet Trust - Tibet Trust commits not to reduce its holdings in the acquired shares for 12 months following the transfer [2][10]. 3. Approval and Compliance - The transfer requires approval from Tonghua Dongbao's shareholders' meeting, compliance confirmation from the Shanghai Stock Exchange, and registration with the China Securities Depository and Clearing Corporation [2][10]. 4. Parties Involved - The transferor is Tonghua Dongbao Pharmaceutical Co., Ltd., and the transferee is Tibet Trust Co., Ltd., representing the "Tibet Trust - Jintong No. 35 Collective Fund Trust Plan" [4][5]. 5. Payment Terms - The payment for the shares will be made in installments, with the first payment of 10 million yuan due within three trading days after the agreement is effective [5][6]. 6. Confidentiality and Dispute Resolution - Both parties agree to maintain confidentiality regarding the agreement's content, with specific exceptions outlined [6][7]. - Disputes will be resolved through litigation if not settled through negotiation within 30 days [7][8]. 7. Other Provisions - The agreement will be effective upon signing and after approval from the shareholders' meeting [8][10]. - Any taxes and fees related to the transfer will be borne by the respective parties [8].

证券代码：688278 证券简称：特宝生物 厦门特宝生物工程股份有限公司 简式权益变动报告书 上市公司名称：厦门特宝生物工程股份有限公司 上市地点：上海证券交易所 股票简称：特宝生物 股票代码：688278 信息披露义务人：西藏信托有限公司（代表"西藏信托-金桐35号集合资金 信托计划"） 住所：西藏拉萨市经济开发区博达路1号阳光新城别墅区A7栋 通讯地址：北京市朝阳区金桐西路10号远洋光华国际C座1708A 股份变动性质：股份增加 签署日期：2025年5月22日 声 明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告 书》等相关法律、法规和规范性文件编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在厦门特宝生物工程股份有限公司拥有权益 的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-019 厦门特宝生物工程股份有限公司 关于持股 5%以上股东协议转让部分股份 暨权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 厦门特宝生物工程股份有限公司（以下简称"公司"或"特宝生物"）持 股 5%以上股东通化东宝药业股份有限公司（以下简称"通化东宝"）与西藏信托 有限公司（代表"西藏信托-金桐 35 号集合资金信托计划"）（以下简称"西藏信 托"）签署了《股份转让协议》，通化东宝拟将其持有的 23,187,600 股公司股份（以 下简称"标的股份"）以 56.12 元/股的价格转让给西藏信托，转让股份占公司总 股本的 5.70%。 本次协议转让完成后，通化东宝持有公司的股份数量为 42,012,514 股， 占公司总股本的 10.33%；西藏信托持有公司的股份数量为 23,187,600 股，占公 司总股本的 5.70%。 基于对公司未来持续发展的信心和长期投资价值的认可，西藏信托承诺 自标的股份完成过户登记之日起 ...

证券代码：688278 证券简称：特宝生物 厦门特宝生物工程股份有限公司 简式权益变动报告书 上市公司名称：厦门特宝生物工程股份有限公司 信息披露义务人：通化东宝药业股份有限公司 公司住址/通讯地址：吉林省通化县东宝新村 股份变动性质：股份减少 签署日期：2025年5月22日 1 上市地点：上海证券交易所 股票简称：特宝生物 股票代码：688278 声 明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告 书》等相关法律、法规和规范性文件编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在厦门特宝生物工程股份有限公司拥有权益 的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在厦门特宝生物工程股份有限公司中拥有权益的 股份。 四、本次权益变动是根据本报告书所载明的资料进 ...